These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3698053)

  • 1. Phase II evaluation of weekly cisplatin in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group Trial.
    Moore MR; Troner MB; DeSimone P; Birch R; Irwin L
    Cancer Treat Rep; 1986 Apr; 70(4):541-2. PubMed ID: 3698053
    [No Abstract]   [Full Text] [Related]  

  • 2. Phase II evaluation of mitoguazone in metastatic hormone-resistant prostate cancer: a Southeastern Cancer Study Group trial.
    Moore MR; Graham SD; Birch R; Irwin L
    Cancer Treat Rep; 1987 Jan; 71(1):89-90. PubMed ID: 3791273
    [No Abstract]   [Full Text] [Related]  

  • 3. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 4. Melphalan in metastatic cancer of the prostate: a pilot study.
    Franks CR
    Cancer Treat Rep; 1979 Feb; 63(2):228-9. PubMed ID: 445500
    [No Abstract]   [Full Text] [Related]  

  • 5. European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer.
    Jones WG; Fosså SD; Bono AV; Klijn JG; De Pauw M; Sylvester R
    Cancer Treat Rep; 1987 Dec; 71(12):1317-8. PubMed ID: 3480046
    [No Abstract]   [Full Text] [Related]  

  • 6. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.
    Robinson D; Sandblom G; Johansson R; Garmo H; Stattin P; Mommsen S; Varenhorst E;
    J Urol; 2008 Jan; 179(1):117-22; discussion 122-3. PubMed ID: 17997442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastatic prostate carcinoma to the mandible: report of case.
    Mesa ML
    J Oral Surg; 1977 Feb; 35(2):133-5. PubMed ID: 264506
    [No Abstract]   [Full Text] [Related]  

  • 9. [Treatment of advanced prostatic carcinoma with cis-diamminedichloroplatinum].
    Okumura S; Hasegawa J; Ohhara M; Kawamura N; Abe H; Yui Y; Kanamori S; Yoshida K; Nishimura T; Tomita M
    Hinyokika Kiyo; 1984 Dec; 30(12):1801-7. PubMed ID: 6543417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study.
    Qazi R; Khandekar J
    Am J Clin Oncol; 1983 Apr; 6(2):203-5. PubMed ID: 6681933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The acid and alkaline phosphatase activity in the serum of patients with prostatic cancer. The effect of endocrine therapy].
    Thijs LG; Poelman JR; Noll WL
    Ned Tijdschr Geneeskd; 1969 Jul; 113(30):1303-9. PubMed ID: 5802998
    [No Abstract]   [Full Text] [Related]  

  • 12. [Phase II study on cis-diamminedichloroplatinum (II) by a collaborative study].
    Gan To Kagaku Ryoho; 1982 Jan; 9(1):46-54. PubMed ID: 6892191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of spirogermanium in metastatic prostate cancer.
    Dexeus FH; Logothetis C; Samuels ML; Hossan B
    Cancer Treat Rep; 1986 Sep; 70(9):1129-30. PubMed ID: 3742495
    [No Abstract]   [Full Text] [Related]  

  • 14. [The diagnostic value of serum acid phosphatases in carcinoma of the prostate (author's transl)].
    Braun JS; Habig H; Crüsemann D
    Urologe A; 1974 Sep; 13(5):236-41. PubMed ID: 4138057
    [No Abstract]   [Full Text] [Related]  

  • 15. [Evaluation of the effectiveness of cisplatin in the treatment of disseminated cancer of the prostate].
    Nogueira March JL; Ojea A; Jamardo D; Díez E; Figueiredo L
    Arch Esp Urol; 1985; 38(1):28-34. PubMed ID: 4039554
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase II evaluation of cisplatin in squamous carcinoma of the esophagus: a Southeastern Cancer Study Group trial.
    Ravry MJ; Moore MR; Omura GA; Esseese I; Bartolucci A
    Cancer Treat Rep; 1985 Dec; 69(12):1457-8. PubMed ID: 4075322
    [No Abstract]   [Full Text] [Related]  

  • 17. A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil.
    Hsu CH; Cheng AL; Hsu C; Yang CH; Lu YS; Lin CC; Bu CF; Yeh KH
    Anticancer Res; 2002; 22(6B):3621-7. PubMed ID: 12552966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of advanced prostatic carcinoma with medroxyprogesterone.
    Rafla S; Johnson R
    Curr Ther Res Clin Exp; 1974 Apr; 16(4):261-7. PubMed ID: 4208339
    [No Abstract]   [Full Text] [Related]  

  • 19. A phase II evaluation of adriamycin and cis-platinum in hormone resistant prostate cancer.
    Citrin DL; Hogan TF
    Cancer; 1982 Jul; 50(2):201-6. PubMed ID: 7200827
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of cyproterone acetate on advanced carcinoma of the prostate.
    Geller J; Vazakas G; Fruchtman B; Newman H; Nakao K; Loh A
    Surg Gynecol Obstet; 1968 Oct; 127(4):748-58. PubMed ID: 5675191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.